To determine the incidence of ovarian failure after cyclophosphamide (CYC) treatment for systemic lupus erythematosus (SLE) and to identify the risk factors for this complication.
The records of 70 premenopausal female SLE patients treated with CYC were reviewed retrospectively.
Information on demographic features, autoantibody profiles, and CYC treatment was obtained, and comparisons were made between those who developed ovarian failure and those who did not.
Data on the CYC-treated patients were also compared with data on 2 control groups of non-CYC-treated SLE patients.
Eighteen patients developed ovarian failure after CYC treatment, for an overall incidence of 26%. The incidence of ovarian failure showed a linear trend of increase with increasing age at the start of CYC (P=0.007).
The cumulative CYC dose was significantly higher in the patients with ovarian failure than in those without (28.3 gm versus 15.4 gm ; P=0.004).
The risk of ovarian failure also showed a linear trend of increase with increasing cumulative CYC dose (P<0.001).
Using multiple logistic regression, the age at the time of CYC treatment initiation (bêta=0.37, SE=0.11, P=0.001) and the cumulative dose of CYC received (bêta=0.69, SE=0.29, P=0.02) were found to be independent risk factors for CYC-induced ovarian failure. (...)
Mots-clés Pascal : Lupus érythémateux, Disséminé, Traitement, Cyclophosphamide, Chimiothérapie, Toxicité, Insuffisance ovarienne, Adulte, Homme, Femelle, Epidémiologie, Incidence, Facteur risque, Moutarde à l'azote, Oxazaphosphinane dérivé, Peau pathologie, Tissu conjonctif pathologie, Maladie système, Maladie autoimmune, Immunopathologie, Ovaire pathologie, Appareil génital femelle pathologie, Endocrinopathie
Mots-clés Pascal anglais : Lupus erythematosus, Disseminated, Treatment, Cyclophosphamide, Chemotherapy, Toxicity, Ovarian failure, Adult, Human, Female, Epidemiology, Incidence, Risk factor, Nitrogen mustard, Oxazaphosphinane derivatives, Skin disease, Connective tissue disease, Systemic disease, Autoimmune disease, Immunopathology, Ovarian diseases, Female genital diseases, Endocrinopathy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0261676
Code Inist : 002B02U06. Création : 11/09/1998.